2018 Fourth Quarter Conference Call

February 19, 2019 • 8:30 AM ET

Feb 19, 2019 • 7:00 AM EST

FY 2018 Year End Results

Fiscal Year Ended Dec 31, 2018

Consolidated revenue increased 24.5% to $76.5 million

Consolidated revenue increased 17.0% to $71.8 million, excluding Genoptix

Clinical Services revenue increased 23.3% to $65.9 million

Pharma Services revenue increased 32.6% to $10.6 million

NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO





Day Range

52 week Range

IR Contact Information

Investor Relations William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844